Focal-onset seizures (FOSs) are the most common type of seizure experienced by epileptic individuals. A recent randomized control trial published in JAMA Neurology evaluated the effect of a novel ...

Please provide your email address to receive an email when new articles are posted on . Focal cortex stimulation with an implantable device reduced seizure activity in more than 50% of participants at ...

Long-term use of Xcopri was safe and reduced seizures by more than 90% in adults with uncontrolled focal seizures, according to results of an open-label extension study published in Neurology. “The ...

Marinus Pharmaceuticals announced top-line results from the Phase 3 clinical trial of ganaxolone in adults with drug-resistant focal onset seizures. Marinus Pharmaceuticals announced top-line results ...

About 60-70% of focal epilepsy patients achieve seizure control with first-line antiseizure medications (ASMs). Lamotrigine and levetiracetam demonstrate high efficacy and tolerability for seizure ...

Lacosamide Vimpat (lacosamide) can help manage focal seizures in adults and children 4 years and older. It can be used alone (monotherapy) or with another AED (adjunctive therapy). Lacosamide reduces ...

Long-term, real-world evidence demonstrates early and lasting outcomes of adjunctive VNS Therapy on severe focal seizures The CORE-VNS 36-month data analysis reaffirms the effectiveness of VNS Therapy ...

(Reuters) - Marinus Pharmaceuticals Inc said it plans to stop development of its treatment for drug-resistant focal onset seizures in adults after it failed a late-stage trial, sending the company's ...

The US Food and Drug Administration (FDA) has approved cenobamate (Xcopri, SK Life Science) for the treatment of partial-onset seizures in adult patients with epilepsy. Today's approval was based on ...

Patients with focal nonmotor seizures experience a "disproportionate delay to diagnosis" compared with those with focal motor seizures, especially among teens, new research suggests. Retrospective ...